Biliary atresia diagnosis accelerated by combining bilirubin testing and feeding ultrasound. New strategy from Texas Children's Hospital aims to improve early detectionBiliary atresia diagnosis accelerated by combining bilirubin testing and feeding ultrasound. New strategy from Texas Children's Hospital aims to improve early detection

New Pathway Aims to Detect Biliary Atresia Earlier in Infants

2026/07/04 15:00
4 min di lettura
Per feedback o dubbi su questo contenuto, contattateci all'indirizzo crypto.news@mexc.com.

Biliary atresia (BA), a rare but serious liver disease in infants, can progress rapidly from subtle newborn signs to irreversible liver injury. Early treatment with Kasai portoenterostomy (KP) offers the best chance of delaying or avoiding liver transplantation, yet many infants are still diagnosed after the most favorable treatment window has passed. A newly described clinical strategy, developed by researchers from Texas Children’s Hospital, Baylor College of Medicine, and Stanford University School of Medicine, aims to shorten this delay by pairing two practical steps: direct or conjugated bilirubin (DB/Bc) measurements and a feeding abdominal ultrasound exam.

The approach is detailed in a review published on March 16, 2026, in the World Journal of Pediatric Surgery (DOI: 10.1136/wjps-2025-001142). The researchers describe a streamlined pathway developed at a Texas pediatric center to accelerate BA diagnosis by combining DB/Bc testing, interpretation through BiliScreen.org, and a feeding ultrasound approach focused on key biliary imaging signs.

BA is difficult to detect because early jaundice can resemble common newborn conditions, and pale stools may not appear immediately. The disease is thought to begin before birth, when the extrahepatic bile ducts do not form properly. After birth, bile builds up in the liver, driving progressive injury and increasing the likelihood of liver transplantation. Studies have shown that infants treated before 30–45 days of life tend to have better long-term outcomes, but diagnosis is often delayed beyond 60 days.

The first step of the new pathway uses DB/Bc measurements in the newborn nursery and early outpatient visits. The review highlights evidence that DB/Bc levels can be elevated in the first 24–48 hours of life in infants with BA, before clear clinical signs or other liver injury markers emerge. Primary care providers (PCPs) are also guided to test DB/Bc levels at 2–4 weeks when infants have persistent jaundice, pale stools, or a previous high DB/Bc result, consistent with American Academy of Pediatrics (AAP) guidance.

The second step is a feeding abdominal ultrasound exam for infants with high DB/Bc levels. Instead of requiring fasting, the infant feeds before or during imaging, which can make the duct at the hilum (DaH) easier to visualize. The exam also measures maximum echogenicity (MxE) near the right portal vein. In the proposed workflow, an MxE greater than 4.0 mm or an absent DaH raises concern for BA and may prompt definitive evaluation, while other findings may support continued outpatient assessment.

The authors said the strategy is designed to make early BA evaluation more actionable for the full care team, from nursery providers and PCPs to radiologists, hepatologists, and surgeons. They said the aim is not to replace specialists’ judgment, but to give clinicians clearer signals at the moment when time matters most. By sharing the pathway, they hope other centers will provide feedback, test the approach in different practice settings, and adapt useful parts into their own workflows.

The potential implications are broad. Universal newborn DB/Bc screening could reduce delays and may also help address disparities in diagnosis by identifying risk before visual signs are missed or misread. The feeding ultrasound approach could make follow-up evaluation less burdensome by avoiding fasting and potentially reducing reliance on tests that require anesthesia or invasive procedures. For families, earlier detection could mean faster treatment decisions and a better chance of preserving the native liver. Future studies will need to evaluate implementation, cost-effectiveness, and performance across multiple centers and healthcare systems.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is New Pathway Aims to Detect Biliary Atresia Earlier in Infants.

The post New Pathway Aims to Detect Biliary Atresia Earlier in Infants appeared first on citybuzz.

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: gli articoli ripubblicati su questo sito provengono da piattaforme pubbliche e sono forniti esclusivamente a scopo informativo. Non riflettono necessariamente le opinioni di MEXC. Tutti i diritti rimangono agli autori originali. Se ritieni che un contenuto violi i diritti di terze parti, contatta crypto.news@mexc.com per la rimozione. MEXC non fornisce alcuna garanzia in merito all'accuratezza, completezza o tempestività del contenuto e non è responsabile per eventuali azioni intraprese sulla base delle informazioni fornite. Il contenuto non costituisce consulenza finanziaria, legale o professionale di altro tipo, né deve essere considerato una raccomandazione o un'approvazione da parte di MEXC.